Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 1 | 56.6% | +41.3% |
| PARKIN, JEFFREY S | 1 | 63.7% | +21.3% |
| FISCHER, JOSEPH | 1 | 43.3% | +45.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245991 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | FISCHER, JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246122 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTI-PEG ANTIBODIES IN A PATIENT | LIPPERT, JOHN WILLIAM | 14d |
| 18246117 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | PARKIN, JEFFREY S | 62d |
| 18245991 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1671 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246122 | COMPOUND FOR THE SEQUESTRATION OF UNDESIRABLE ANTI-PEG ANTIBODIES IN A PATIENT | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 14d | Pending | Mar 21, 2023 |
| 18246117 | COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | 62d | Pending | Mar 21, 2023 |
| 18245991 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | FISCHER, JOSEPH | 1658 | §102§103§112Other | Non-Final OA | — | Pending | Mar 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial